Euthymics Bioscience, Inc. Initiates Clinical Trial for New Drug Targeted for Adult Attention Deficit Hyperactivity Disorder (ADHD)
3/22/2012 6:35:07 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Euthymics Bioscience, Inc. today announced that it has initiated a Phase 1 clinical trial of EB-1020, a next-generation drug in development for treating adult attention deficit hyperactivity disorder (ADHD), with low risk of drug abuse liability. This would meet a critical need because current stimulants used to treat ADHD are tightly regulated and often in short supply due to their addictive properties. Peer-reviewed preclinical data demonstrated that EB-1020 affects areas of the brain associated with ADHD. Dosing of healthy volunteers in the EB-1020 Phase 1 trial is now underway. Final results of the study are expected late this summer.
comments powered by